Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib Study of Losartan, Pembrolizumab and Stereotactic Body Radiation Therapy (SBRT) in Patients With Locoregionally Recurrent, Refractory, or Oligometastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

NCT06211335 is registered in ClinicalTrials.gov with University of California, Davis as lead sponsor.

NCT NCT06211335
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06211335 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib Study of Losartan, Pembrolizumab and Stereotactic Body Radiation Therapy (SBRT) in Patients With Locoregionally Recurrent, Refractory, or Oligometastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Lead sponsor
University of California, Davis
Phase
Phase 1
Overall status
Recruiting
Start date
December 7, 2023
Completion date
June 30, 2027
Enrollment
24 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

locally recurrent head and neck squamous cell carcinoma, metastatic head and neck squamous cell carcinoma, refractory head and neck squamous cell carcinoma